This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Germer, J. J.
Right arrow Articles by Patel, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germer, J. J.
Right arrow Articles by Patel, R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2002, p. 495-500, Vol. 40, No. 2
0095-1137/01/$04.00+0     DOI: 10.1128/JCM.40.2.495-500.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Comparative Evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR Version 2.0 Assays for Quantification of Hepatitis C Virus RNA in Serum

Jeffrey J. Germer,1 Paul J. Heimgartner,1 Duane M. Ilstrup,2 W. Scott Harmsen,2 Greg D. Jenkins,2 and Robin Patel1,3*

Division of Clinical Microbiology,1 Division of Infectious Diseases,3 Section of Biostatistics, Mayo Clinic, Rochester, Minnesota2

Received 12 March 2001/ Returned for modification 13 August 2001/ Accepted 9 November 2001

A comparison of quantitative results expressed in hepatitis C virus (HCV) international units per milliliter, obtained from the VERSANT HCV RNA 3.0 (bDNA-3.0) assay, the QUANTIPLEX HCV RNA 2.0 (bDNA-2.0) assay, and the COBAS AMPLICOR HCV MONITOR version 2.0 (HCM-2.0) test was performed. A total of 168 patient specimens submitted to the Mayo Clinic Molecular Microbiology Laboratory for HCV quantification or HCV genotyping were studied. Of the specimens tested, 97, 88, and 79% yielded quantitative results within the dynamic range of the bDNA-3.0, bDNA-2.0, and HCM-2.0 assays, respectively. Overall, there was substantial agreement between the results generated by all three assays. A total of 15 out of 29 (52%) of the specimens determined to contain viral loads of <31,746 IU/ml by the bDNA-3.0 assay were categorized as containing viral loads within the range of 31,746 to 500,000 IU/ml by the bDNA-2.0 assay. Although substantial agreement was noted between the results generated by the bDNA-2.0 and bDNA-3.0 assays, a bias toward higher viral titer by the bDNA-2.0 assay was noted (P = 0.001). Likewise, although substantial agreement was noted between the results generated by the HCM-2.0 and bDNA-3.0 assays, a bias toward higher viral titer by the bDNA-3.0 assay was noted (P <= 0.001). The discrepancy between the HCM-2.0 and bDNA-3.0 results was more pronounced when viral loads were >500,000 IU/ml and resulted in statistically significant differences (P <= 0.001) in determining whether viral loads were above or below 800,000 IU/ml of HCV RNA, the proposed threshold value for tailoring the duration of combination therapy. The expression of quantitative values in HCV international units per milliliter was a strength of both the bDNA-3.0 and HCM-2.0 assays.

* Corresponding author. Mailing address: Division of Infectious Diseases, Mayo Clinic, 200 First St. SW, Rochester, MN 55905. Phone: (507) 255-6482. Fax: (507) 255-7767. E-mail: patel.robin{at}mayo.edu.

Journal of Clinical Microbiology, February 2002, p. 495-500, Vol. 40, No. 2
0095-1137/01/$04.00+0     DOI: 10.1128/JCM.40.2.495-500.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chevaliez, S., Bouvier-Alias, M., Pawlotsky, J.-M. (2009). Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification. J. Clin. Microbiol. 47: 1726-1732 [Abstract] [Full Text]  
  • Sarrazin, C., Gartner, B. C., Sizmann, D., Babiel, R., Mihm, U., Hofmann, W. P., von Wagner, M., Zeuzem, S. (2006). Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5.. J. Clin. Microbiol. 44: 729-737 [Abstract] [Full Text]  
  • Konnick, E. Q., Williams, S. M., Ashwood, E. R., Hillyard, D. R. (2005). Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan Analyte-Specific Reagent Assay and Comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 Assays. J. Clin. Microbiol. 43: 2133-2140 [Abstract] [Full Text]  
  • Barbeau, J. M., Goforth, J., Caliendo, A. M., Nolte, F. S. (2004). Performance Characteristics of a Quantitative TaqMan Hepatitis C Virus RNA Analyte-Specific Reagent. J. Clin. Microbiol. 42: 3739-3746 [Abstract] [Full Text]  
  • Schuttler, C. G., Thomas, C., Discher, T., Friese, G., Lohmeyer, J., Schuster, R., Schaefer, S., Gerlich, W. H. (2004). Variable Ratio of Hepatitis C Virus RNA to Viral Core Antigen in Patient Sera. J. Clin. Microbiol. 42: 1977-1981 [Abstract] [Full Text]  
  • Elbeik, T., Surtihadi, J., Destree, M., Gorlin, J., Holodniy, M., Jortani, S. A., Kuramoto, K., Ng, V., Valdes, R. Jr., Valsamakis, A., Terrault, N. A. (2004). Multicenter Evaluation of the Performance Characteristics of the Bayer VERSANT HCV RNA 3.0 Assay (bDNA). J. Clin. Microbiol. 42: 563-569 [Abstract] [Full Text]  
  • Morishima, C., Chung, M., Ng, K. W., Brambilla, D. J., Gretch, D. R. (2004). Strengths and Limitations of Commercial Tests for Hepatitis C Virus RNA Quantification. J. Clin. Microbiol. 42: 421-425 [Abstract] [Full Text]  
  • Richter, S. S. (2002). Laboratory Assays for Diagnosis and Management of Hepatitis C Virus Infection. J. Clin. Microbiol. 40: 4407-4412 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»